Sacubitril/Valsartan: From Clinical Trials to Real-world Experience.

Abstract

PURPOSE OF REVIEW:

Compared to enalapril, use of angiotensin-receptor blocker and neprilysin inhibitor sacubitril/valsartan to treat patients with heart failure and reduced ejection fraction (HFrEF) is associated with substantial reductions in both cardiovascular mortality and heart failure progression. The purpose of this review is to discuss the real-world experience of sacubitril/valsartan.

RECENT FINDINGS:

In the years following the publication of the landmark PARADIGM-HF trial in 2014 and its subsequent FDA approval, a growing evidence base supports the safety and efficacy of sacubitril/valsartan in a broad spectrum of patients with HFrEF. Updated clinical practice guidelines have embraced the use of sacubitril/valsartan in preference to ACE inhibitors or ARBs in selected patients. In this review, we highlight the clinical trials that led to these key updates to clinical guidelines, offer practical strategies for patient selection and utilization in clinical practice, and identify important areas of uncertainty that require future research.

• Authors: Joanna M Joly, Akshay S Desai
• Journal: Current treatment options in cardiovascular medicine (Curr Treat Options Cardiovasc Med) Vol. 20 Issue 6 Pg. 45 (Apr 23 2018) ISSN: 1092-8464 [Print] United States
• PMID: 29687191 (Publication Type: Journal Article, Review)